Last updated on November 2019

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer


Brief description of study

The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.

Clinical Study Identifier: NCT02743494

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.